Literature DB >> 7247733

Hypolipidemic and hypouricemic action of fenofibrate in various types of hyperlipoproteinemias.

C Harvengt, F Heller, J P Desager.   

Abstract

Fenofibrate, a phenoxyacid derivative, given at daily dose of 300mg during 1 year following a single blind design, lowered significantly serum triglycerides and total cholesterol in patients various types of hyperlipoproteinemias (IIa, IV, V), fibrate significantly reduced plasma uric acid. Side effects were few after prolonged treatment. Moderate and transient increases in creatine phosphokinase and glutamopyruvic transaminase values were shown in some patients. An interaction with oral anticoagulants was also observed.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7247733

Source DB:  PubMed          Journal:  Artery        ISSN: 0098-6127


  12 in total

1.  Fenofibrate and losartan.

Authors:  T Bardin
Journal:  Ann Rheum Dis       Date:  2003-06       Impact factor: 19.103

Review 2.  Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia.

Authors:  J C Adkins; D Faulds
Journal:  Drugs       Date:  1997-10       Impact factor: 9.546

Review 3.  Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia.

Authors:  J A Balfour; D McTavish; R C Heel
Journal:  Drugs       Date:  1990-08       Impact factor: 9.546

4.  Lack of pharmacokinetic interaction of colestipol and fenofibrate in volunteers.

Authors:  C Harvengt; J P Desager
Journal:  Eur J Clin Pharmacol       Date:  1980-06       Impact factor: 2.953

Review 5.  Targeting hypoxic response for cancer therapy.

Authors:  Elisa Paolicchi; Federica Gemignani; Marija Krstic-Demonacos; Shoukat Dedhar; Luciano Mutti; Stefano Landi
Journal:  Oncotarget       Date:  2016-03-22

6.  Effects of clofibrate, bezafibrate, fenofibrate and probucol on plasma lipolytic enzymes in normolipaemic subjects.

Authors:  F Heller; C Harvengt
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

7.  Effect of a single daily dose treatment of fenofibrate on plasma lipoproteins in hyperlipoproteinaemia IIb.

Authors:  S Bertolini; N Elicio; A Daga; M L Degl'Innocenti; R Balestreri; M G Fusi; A M Cotta Ramusino; A Carozzi
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 8.  Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia.

Authors:  Gillian M Keating; Douglas Ormrod
Journal:  Drugs       Date:  2002       Impact factor: 9.546

9.  Effects of a salt of cholestyramine and 2-[4-(p-chlorobenzoyl)phenoxy]2-methyl propionic acid (alpha-1081) on biliary lipid secretion in rats.

Authors:  R Aldini; L Barbara; A Benelli; V Borzatta; S Geminiani; G Mascellani; A Morselli; A Roda; E Roda
Journal:  Br J Pharmacol       Date:  1981-11       Impact factor: 8.739

10.  Identification of Febuxostat as a New Strong ABCG2 Inhibitor: Potential Applications and Risks in Clinical Situations.

Authors:  Hiroshi Miyata; Tappei Takada; Yu Toyoda; Hirotaka Matsuo; Kimiyoshi Ichida; Hiroshi Suzuki
Journal:  Front Pharmacol       Date:  2016-12-27       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.